Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | NOS1 | P29475 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833974 | 0.82 | CYP11B1 (0.44) | CYP11B1CYP11B2NOS1CYP3A4CYP2D6 | |
| SCHEMBL14243162 | 0.79 | CYP11B1 (0.43) | CYP11B1CYP11B2NOS1CYP3A4CYP2D6 | |
| SCHEMBL16100223 | 0.79 | CYP11B2 (0.61) | CYP11B1CYP11B2 | |
| SCHEMBL13153540 | 0.68 | HPGD (0.46) | — | |
| SCHEMBL899423 | 0.67 | CYP11B2 (0.35) | CYP11B1CYP11B2NOS1 | |
| SCHEMBL9473672 | 0.66 | NOTUM (0.43) | CYP11B1CYP11B2NOS1 | |
| SCHEMBL10872204 | 0.65 | CYP2C19 (0.38) | CYP11B1CYP11B2NOS1 | |
| SCHEMBL20599514 | 0.64 | NPC1 (0.40) | CYP11B1CYP11B2NOS1CYP3A4CYP2D6 | |
| SCHEMBL5317934 | 0.63 | — | — | |
| SCHEMBL10235433 | 0.63 | NOS1 (0.49) | CYP11B1CYP11B2NOS1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349873-B2 | Factor XA inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-20120088795-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063077-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20110118244-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249117-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086188-A2 | THIOPHENE CARBOXAMIDES AS FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007131179-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185092-A1 | FACTOR Xa INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185092-A1 | FACTOR Xa INHIBITORS | TFPI, F12, F11 | CYP11B1 410/4885CYP11B2 474/4885NOS1 1685/4885 |
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP11B1 289/4885CYP11B2 339/4885NOS1 1564/4885 |
| US-20110118244-A2 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP11B1 289/4885CYP11B2 339/4885NOS1 1564/4885 |
| US-20100249117-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP11B1 289/4885CYP11B2 339/4885NOS1 1564/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP11B1 289/4885CYP11B2 339/4885NOS1 1564/4885 |
| US-20120088795-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | CYP11B1 289/4885CYP11B2 339/4885NOS1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.